



**MODERN
ART
FOR SOUTH AFRICA**



ABOUT MODERN ART







MODERN ART

LEARN MORE

ART & Pregnancy

ART & TB

ART & COVID-19

ART & HIV

LATEST NEWS

About us

ModernART leads at Kinglerberg correctional facility

ModernART joins Kigamam pink

Let's talk about COVID-19

FOLLOW US

GET THE FREE APP

MODERNARTforSOUTHAFRICA.CO.ZA

IF I AM HIV+ DO I HAVE TO DISCLOSE MY HIV STATUS TO GET THE VACCINE?

NO!

BUT you might be asked what medication you are taking.

HI POSITIVE

MODERNARTforSOUTHAFRICA.CO.ZA

LESTER BALOYI

*****IMPORTANT NEW TREATMENT INFO*****

ART & TB

EVERYONE STARTING ART WILL BE TESTED FOR TB

CTV POSITIVE

MODERN ART FOR SOUTH AFRICA

SWITCHING & SECOND-LINE ART

Everyone with HIV needs to take HIV treatment - called antiretroviral therapy, ART or ARV.

AHD NDI... Famahe mabandla eminyanzane eminyanzane maza maza! Amantsole COA yaba elipheleli yaba yaba.

HIV POSITIVE

NDI ZIZINDIKIRO IZ!

THE ARTIST - a possibility for us to create a culture of artistic expression

ART & TB

MODERN ART FOR NIGERIA

ART MEDICINE PREGNANCY AND WOMAN BODY

Everyone with HIV needs to take HIV treatment - called antiretroviral therapy, ART or ARV.

*****IMPORTANT HIV TREATMENT INFO*****

THE ART COMBINATION IS CHANGING IN SOUTH AFRICA

EVERYONE WITH HIV NEEDS TO TAKE HIV TREATMENT - CALLED ANTIRETROVIRAL THERAPY, ART or ARV.

ART is usually three ARVs in one pill - called a fixed dose combination.

THE NEW COMBINATION tenofovir, lamivudine and dolutegravir. This combination is called TLD.

HI POSITIVE



IF YOU DON'T HAVE TB Start ART and TB preventative therapy.

IF YOU DO HAVE TB Start TB treatment and ART between 2 and 8 weeks later. People with low CD4 counts need to start sooner. You will be given an extra dose of dolutegravir when you start ART on TB treatment.

HI POSITIVE

EVERYONE WITH HIV NEEDS TO TAKE HIV TREATMENT - CALLED ANTIRETROVIRAL THERAPY, ART or ARV.

ART & TB

EVERYONE STARTING ART WILL BE TESTED FOR TB

ADVANCED HIV

Everyone with HIV needs to take HIV treatment - called antiretroviral therapy, ART or ARV.



THE NEW COMBINATION tenofovir, lamivudine and dolutegravir. This combination is called TLD.

HI POSITIVE

IF I AM HIV+ DOES THE COVID VACCINE WORK?

YES!

Vaccines are safe for people living with HIV, and can be used with antiretrovirals.

HI POSITIVE

MODERNARTforSOUTHAFRICA.CO.ZA

THE NEW ENGLAND JOURNAL OF MEDICINE

Stratigine plus The Different Findings of Studies in Year 2021

MODERN ART IS COMING TO KLIPTOWN!

STARTING ART

Everyone with HIV needs to take HIV treatment - called antiretroviral therapy, ART or ARV.

ART PREGNANCY & WOMEN'S HEALTH

Everyone with HIV needs to take HIV treatment - called antiretroviral therapy, ART or ARV.

*****IMPORTANT HIV TREATMENT INFO FOR WOMEN*****

THE ART COMBINATION IS CHANGING IN SOUTH AFRICA

THE NEW ART COMBINATION IS: Tenofovir + Lamivudine + Dolutegravir. This is called TLD.

EVERYONE WITH HIV NEEDS TO TAKE HIV TREATMENT - CALLED ANTIRETROVIRAL THERAPY, ART or ARV.

TLD IS RECOMMENDED FOR ALL WOMEN - INCLUDING PREGNANT WOMEN

IF I AM HIV+ DOES THE COVID VACCINE WORK?

YES!

Vaccines are safe for people living with HIV, and can be used with antiretrovirals.

HI POSITIVE

MODERNARTforSOUTHAFRICA.CO.ZA

IF I AM HIV+ DOES THE COVID VACCINE WORK?

YES!

Vaccines are safe for people living with HIV, and can be used with antiretrovirals.

HI POSITIVE

MODERNARTforSOUTHAFRICA.CO.ZA

MODERN ART FOR SOUTH AFRICA

THE COVID-19 VACCINE

Everything you need to know about COVID-19 vaccines

OCTOBER 2021

THE NEW KID ON THE BLOCK

COVID

MAKE SURE YOU GET ALL THE INFORMATION YOU NEED TO MAKE THE RIGHT DECISION FOR YOU

ALL HIV POSITIVE WOMEN SHOULD BE TOLD OF THEIR OPTIONS TO HELP THEM CHOOSE THE RIGHT ART COMBINATION

IF I AM HIV+ DOES THE COVID VACCINE WORK?

YES!

Vaccines are safe for people living with HIV, and can be used with antiretrovirals.

HI POSITIVE

MODERNARTforSOUTHAFRICA.CO.ZA



MODERN ART FOR SOUTH AFRICA

THE COVID-19 VACCINE

Everything you need to know about COVID-19 vaccines

OCTOBER 2021





Modern ART for South Africa began as a collaboration between the Treatment Action Campaign (TAC) and HIV i-Base.

The project was set up in 2016 to provide treatment literacy resources and training to communities in South Africa. It was developed primarily to support the ADVANCE study – which compared HIV treatments – and the introduction of a new dolutegravir-based national first-line regimen.

From 2016 to 2022, Modern ART was funded by Unitaid as part of their ART Optimisation Portfolio.

This period has been one of many highs and lows for HIV in South Africa: from the news that about 5.5 million people across the country have started ART, to the onerous effects of COVID-19.



WHY MODERN ART?









Despite HIV having been with us for over 40 years, with effective treatment for almost 30 of them (yet responsible for over 32 million deaths), HIV-associated stigma is still very real.



We chose the name Modern ART (ART is an abbreviation for antiretroviral therapy, used worldwide to treat HIV), so that people did not have to worry about being seen with materials – such as the pocket-sized booklets and app – that make HIV too obvious.



Most medical information is dull at best and presentation is not a big consideration – so we wanted to send a very positive message with our visual identity. Our aim is to provide resources that people wanted to pick up, go and look at, talk about with their family and friends and otherwise engage with.



BOOKLETS & POSTERS





MODERN ART FOR

STAIRS

HIV

& Every

MODERN ART FOR

ADVANCED HIV

Everyone needs

MODERN ART FOR

PREGNANT & WOMEN

Everyone needs

MODERN ART FOR AFRICA

ART &

Everyone with HIV needs to take HIV treatment - and ART & SWITCHING

ART & SWITCHING
SECOND-LINE ART

MODERN ART FOR EVERYONE

MODERN ART FOR SOUTH AFRICA

STARTING ART

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2022

MODERN ART FOR SOUTH AFRICA

ART & TB

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2022

MODERN ART FOR SOUTH AFRICA

ART PREGNANCY & WOMEN'S HEALTH

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2022

MODERN ART FOR SOUTH AFRICA

PrEP FOR SOUTH AFRICA

This leaflet is about PrEP
PrEP protects you from HIV even if you don't use a condom

NOVEMBER 2022

MODERN ART FOR SOUTH AFRICA

WHAT IS MODERN ART FOR SOUTH AFRICA

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2022

MODERN ART FOR SOUTH AFRICA

VERSIONS OF ART (TLD)

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2022

MODERN ART FOR SOUTH AFRICA

ADVANCED HIV

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2022

IMPORTANT HIV TREATMENT INFO

THE ART COMBINATION IS CHANGING IN SOUTH AFRICA

EVERYONE WITH HIV NEEDS TO TAKE HIV TREATMENT – CALLED ANTIRETROVIRAL THERAPY, ART OR ARVs.

ART is usually three ARVs in one pill – called a fixed dose combination.

THE NEW COMBINATION
tenofovir, lamivudine and dolutegravir.
This combination is called TLD.

TAC | i-bare | Unitaid

IMPORTANT HIV TREATMENT INFO

THE NEW ART COMBINATION CALLED TLD IS HERE!

THEY LOOK DIFFERENT, BUT IT IS THE SAME MEDICINE!

There are several different versions of TLD. Don't be surprised if your tablets change. Or they don't look the same as your family or friend's HIV medicine! Packaging can also look different for the same medicine.

VERSIONS OF TLD PILLS & PACKAGING WHICH ARE EXACTLY THE SAME MEDICINE

TAC | i-bare | Unitaid

IMPORTANT HIV TREATMENT INFO FOR WOMEN

THE ART COMBINATION IS CHANGING IN SOUTH AFRICA

THE NEW ART COMBINATION IS:
Tenofovir + Lamivudine + Dolutegravir

EVERYONE WITH HIV NEEDS TO TAKE HIV TREATMENT – CALLED ANTIRETROVIRAL THERAPY, ART OR ARVs.

TLD IS RECOMMENDED FOR ALL WOMEN – INCLUDING PREGNANT WOMEN

MAKE SURE YOU GET ALL THE INFORMATION YOU NEED TO MAKE THE RIGHT DECISION FOR YOU

ALL HIV POSITIVE WOMEN SHOULD BE TOLD OF THEIR OPTIONS TO HELP THEM CHOOSE THE RIGHT ART COMBINATION

TAC | i-bare | Unitaid

IMPORTANT NEW TREATMENT INFO

ADVANCED HIV DISEASE


ADVANCED HIV MEANS illness that happens when some CD4 count is low

- Everyone diagnosed with HIV, coming back to HIV care or doing poorly on HIV treatment should get a CD4 test.
- The best way to prevent advanced HIV disease is to start ART when your CD4 count is high.
- Anyone with AIDS will need some tests and drugs to prevent or treat certain illnesses.

WATCH OUT FOR THESE SERIOUS DANGERS

IN ADULTS & ADOLESCENTS	IN CHILDREN & BABIES
<ul style="list-style-type: none"> Shortness of breath Rapid heart beat Unable to walk without help High temperature 	<ul style="list-style-type: none"> Sleepiness Unconsciousness Convulsions (violent, irregular movement) High temperature

TAC | i-bare | Unitaid



Pocket-sized booklets provide information in simple language to support people with HIV treatment and prevention. We also have information about coinfections, particularly tuberculosis and COVID-19.

The posters have summaries of the same information.

The booklets and posters are designed with and for people living with HIV and activists. They are distributed free through community groups and clinics.






WHAT IS A NEURAL TUBE DEFECT?

The neural tube in a developing baby is what becomes the brain, spinal cord, skull and spine.

The neural tube closes in the first 28 days of pregnancy – that is before most women know they are pregnant.

If it does not fully close for some reason, the baby is said to have a neural tube defect.



Neural tube defects vary, from very minor ones that are easily fixed, to ones that give severe disability and even death.

So, the risk was taken very seriously by the department of health, health workers and patients.


WHAT ARE THE SIDE EFFECTS OF DOLUTEGRAVIR?

These are not common but can include mood changes and difficulty sleeping.

Occasionally people might need to change to another ARV.

Some people find it better to take dolutegravir in the morning than the evening.

Some people gain weight on dolutegravir. South African guidelines encourage everyone to eat a healthy diet and exercise.



Two big issues emerged during the first few years of Modern ART.

The first was a potential safety signal for babies born to women receiving dolutegravir at conception. We needed to explain the risk and benefits in a matter-of-fact, non-scary way in our publications.

The second was the (as yet unresolved) issue of sometimes significant weight gain associated with newer HIV treatments. We have had to balance making sure that people remain on their treatment with explaining what is known and potential strategies to help manage this.

WEBSITE & APP











All our resources are available on our website and our app.

The website includes news stories including of our own activities.

Our app also includes tools to help people manage their own treatment.



TALKING BOOK









There are still many South Africans for whom more conventional ways of sharing information might not be accessible – particularly in rural areas.

The hurdles range from stigma and adult illiteracy, to language barriers, high data costs and unreliable access to electricity.






So, for harder-to-reach communities we also produced a solar-powered talking book, which narrates the information in several local languages (as well as English).

TRAININGS









We have an extensive training programme.

This takes a cascade approach, starting at a national level for the TAC trainers, conducted by experts from and associated with the Modern ART programme. The trainers then take this information out into TAC branches, clinics and community groups across the country.

Our website includes a training manual, with all the basic information.

VIDEO

YouTube ^{ZA}

HOME

VIDEOS



Caclot Dlephu Mobile Clinic

1 year ago



Thanks to SenzaART911

Painting the murals

2 years ago

Search



PLAYLISTS

COMMUNITY

CHANNELS

ABOUT



0:29



8:35

COVID 19 Vaccine PFIZER BIONTECH

1 year ago



11:27

COVID 19 Vaccines: J&J

1 year ago



2:11



2:19

Q&A 2 undetectable

2 years ago



2:02

Modern ART Q&A: ARVs and Reinfection

2 years ago




29

1 year ago



Intro

2 years ago





Like almost all activities across the world, the programme took quite a hit from COVID-19.

At the peak of the pandemic, gatherings were out of the question, so we needed to be nimble and find other ways to share information.

Our YouTube channel includes all the information from our various resources, presented by TAC trainers and these videos are also on the website. As well as those, we produced regular shorter clips in local languages and animation to be distributed by WhatsApp and other platforms.

ACTIVATIONS





WHAT IS PREP?

PREP STANDS FOR
PRE-EXPOSURE
PROPHYLAXIS

WHEN SHOULD I
START HIV TREATMENT?

EVERYONE WHO TESTS
SHOULD START
AT





To ensure that we reach members of the community, we have conducted activations across the country.

We work with graffiti artists to create brightly-coloured murals with our messages. We play music, hand out materials, help people download our app and answer questions about HIV, TB and COVID-19.



More recently we have collaborated with a mobile HIV testing and starting ART or PrEP programme.

SOCIAL MEDIA

MODERN
ART
SOUTH AFRICA

**ASKED
QUESTIONS**

Everyone with HIV
needs to take HIV treatment
- called antiretroviral
therapy, ART or ARVs



GRAFFITI, MUSIC, FREE CONDOMS & BOOKLETS!
HIV POSITIVE
 POSTER GLEN HALL SOWETO
TUESDAY 14 FEB
 10am - 2pm
 ONE POSTER, ONE PHONE, ONE VISA



Bazza Bazza Silal!




MODERN ART IS COMING TO THEMBISE!
24 SEPTEMBER, 10AM-2PM
 WINNE MANDLA ZONE 10
MODERNARTFORSOUTHAFRICA



MODERN ART IS COMING TO HILLBROW!
THURSDAY 1 DECEMBER 2022
 10AM-3PM
 ADJESANT CLINIC HILLBROW CHK
HIV POSITIVE



YOU! YEOVILLE!
MODERN ART IS COMING TO YOU!



AIDS 2022
 29 July - 2 August
MODERN ART SOUTH AFRICA



37



MODERN ART FOR SOUTH AFRICA
THE COVID-19 VACCINE
 Everything you need to know about COVID-19 vaccines



MODERN ART IS COMING TO PHILLIPI!
THURSDAY 21 OCT
 10AM-3PM
 ADJESANT HALL
HIV POSITIVE



MODERN ART IS COMING TO BAZZA BAZZA!
SATURDAY 9 OCT 2021
 10AM-3PM
 2 SANDHURST STREET SOWETO
HIV POSITIVE



MODERN ART IS COMING TO KHAYELITSHA!
18-23 OCTOBER
 VENUE & TIME TO BE CONFIRMED
HIV POSITIVE



MODERN ART IS COMING TO KLIPTOWN!
SATURDAY 4 SEPT 2021
 10AM-2PM
 KLIPTOWN TOWN SQUARE
HIV POSITIVE





ASKED QUESTIONS

Everyone with HIV needs to take HIV treatment - called antiretroviral therapy, ART or ARVs

GRAPEVINE, MUSKIE
FREE CONDOMS & BOOKLETS!
POSTER GLEN HALL
SOWETO
TUESDAY 14 FEB
10am-2pm
CALL PHOENIX
RESOURCES
ON 011 4310

HIV POSITIVE



Bazza Bazza Sila!



MODERN ART IS COMING TO THEMBISE!
24 SEPTEMBER, 10AM-2PM
WINNIE MANDLA
ZONE 10
MODERNARTFORSOUTHAFRICA

days!
stay safe!



MODERN ART IS COMING TO HILLBROW!
THURSDAY
1 DECEMBER 2021
10AM-2PM
ADOLESCENT CLINIC
HILLBROW CEC

HIV POSITIVE



YOU! YEOVILLE!
MODERN ART IS COMING TO YOU!



AIDS 2022
29 July - 2 August

MODERN ART SOUTH AFRICA



MODERN ART FOR SOUTH AFRICA

THE COVID-19 VACCINE
Everything you need to know about COVID-19 vaccines



HIV POSITIVE



MODERN ART IS COMING TO PHILLIPI!
THURSDAY 21 OCT
11AM-2PM
HELI-COMMUNITY HALL

HIV POSITIVE



MODERN ART IS COMING TO BAZZA BAZZA!
SATURDAY
9 OCT 2021
10AM-2PM
2 SENGANGA STREET
SOWETO

HIV POSITIVE



MODERN ART IS COMING TO KHAYELITSHA!
18-23 OCTOBER
COME & TIME TO BE COMFRED

HIV POSITIVE



MODERN ART IS COMING TO KLIPTOWN!
SATURDAY
4 SEPT 2021
10AM-2PM
KLIPTOWN TAKE AWAY

HIV POSITIVE




We also share all our latest activities across our social media platforms.

These have become valuable ways for our followers to ask questions (and receive answers from our team) about their own treatment, prevention and care.

These online Q&As led us to produce a publication with most the frequently asked questions.

INTERNATIONAL



AL



THE ADVANCE STUDY



MODERN ART FOR KENYA

HIV & COVID-19

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2020

MODERN ART FOR KENYA

SWITCHING & SECOND-LINE ART

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2020

MODERN ART FOR UGANDA

ART PREGNANCY & WOMEN'S HEALTH

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2020

MODERN ART FOR ZIMBABWE

MUSHONGA WEKURAPA HIV, PAMUVIRI NEHUTANO HWEHIV

Munhu wese ane hutachiona hweHIV unofanirwa buraire mubhanga wekurapa HIV – ziviro ART kana kuti maARVs

NOVEMBER 2020

MODERN ART FOR NIGERIA

ART MEDICINE PREGNANCY AND WOMAN BODY

Everybody wey get HIV suppose take better treatment with medicine wey dem dey call antiretroviral or ARV.

NOVEMBER 2020

MODERN ART FOR ZIMBABWE

KUTANGA MUSHONGA WEKURAPA HUTACHIONA HWEHIV

Munhu wese ane hutachiona hweHIV unofanirwa buraire mubhanga wekurapa HIV – ziviro ART kana kuti maARVs

NOVEMBER 2020

MODERN ART FOR ZAMBIA

ART PREGNANCY & WOMEN'S HEALTH

Everyone with HIV needs to take HIV treatment – called antiretroviral therapy, ART or ARVs

NOVEMBER 2020

ZOFUNIKIRA KUDZIWA ZA CHITHANDIZO CHA MANKHWALA

ADVANCED HIV DISEASE

AHD NDI...
Pamene matenda osiyanasiyana amaonekera mwa munthu amene CD4 yake ili yotsika kupepera 200.

- Aliyense amene wapatsika ndi HIV, wobwereranso ku thandizo la HIV kapena sakuchita bwino pa kamwedwe ka maARV, ayenera kuyenera CD4.
- Njira yabwino yopewera AHD ndi kuyamba kumwa maARV pamene CD4 ili yokwera.
- Aliyense amene ali ndi AHD ndi woyenera kuyezedwa komanso kulandira mankhwalu opewera kapena kuchiza matenda ena ndi ena.

KHALANI TCHERU NDI ZIZINDIKIRO IZI:

AKULUAKULU NDI ACHINYAMATA

- Kupuma mobanika
- Kuchita phuma
- Kulephera kuyenda opanda wina kukuthandiza
- Kutantha kwa thupi

ANA NDI MAKANDA

- Kusowa tulo
- Kukomoka
- Kusanzanza thupi
- Kukomokakomoka
- Kutantha kwa
- Kukanika kumwa kapena kuyamwa

PEZANI ZAMBURI ZOKHIDZA CHITHANDIZO CHA MANKHWALA KUCHOKERA KWA ACHIPATALA

ibare TAC Unitaid AFROCB

IMPORTANT NEW TREATMENT INFO

ADVANCED HIV DISEASE

ADVANCED HIV MEANS...
illnesses that happen when someone's CD4 cell count is low (below 200)

- Everyone diagnosed with HIV, coming back to HIV care or doing poorly on HIV treatment should get a CD4 test.
- The best way to prevent advanced HIV disease is to start ART when your CD4 count is high.
- Anyone with AHD will need some tests and drugs to prevent or treat certain illnesses.

WATCH OUT FOR THESE SERIOUS DANGER SIGNS:

IN ADULTS & ADOLESCENTS

- Shortness of breath
- Rapid heart beat
- Unable to walk without help
- High temperature

IN CHILDREN & BABIES

- Sleepiness
- Unconsciousness
- Convulsions (violent, irregular movement)
- Unable to drink or breastfeed
- Repeated vomiting
- High temperature

FIND OUT MORE ABOUT TREATMENT FROM YOUR HEALTH CARE PROVIDER

ibare TAC Unitaid AFROCB

MODERN ART FOR NIGERIA



ADVANCED HIV DISEASE (AHD)

A manual for Advanced HIV Disease treatment activists and trainers

MODERN ART FOR UGANDA

ADVANCED HIV DISEASE (AHD)

A manual for Advanced HIV Disease treatment activists and trainers



Our programme has also made its way outside South Africa.

We have attended many international conferences and conducted associated meetings with AfroCAB – a pan-African treatment network.

Through AfroCAB, we have partnered with several community organisations in different African countries to adapt and translate our materials for different local settings.

MODERN ART IN THE MEDIA

MAVERICK CITIZEN

Modern ART paints Soweto bright pink to advertise the latest HIV drug



■ A Modern ART mural painted in Alexandra near the heritage centre on 26 Avenue. (Photo: Nomatter Ndebele)

By Nomatter Ndebele

18 Feb 2021



South Africa's antiretroviral therapy regimen has been upgraded to include the new drug dolutegravir, which has milder side effects for users. Now, SA's Treatment Action Campaign has partnered with i-Base, a British HIV treatment activist charity, to create awareness about the new drug in Soweto.

Listen to this article



0:00 / 3:35

Over a period of fewer than two weeks, 20 bright pink murals began appearing around Soweto and Alexandra townships outside Johannesburg. The murals were positioned in high-visibility locations such as bus stops, community centres, health facilities, schools, taverns and free Wi-Fi hotspots.

The murals were designed by local communication and branding outfit, The Earth is Round. Head designer Karien van der Westhuizen explained that the funky designs were created with a view to modernising the way information about HIV is communicated.

"i-Base asked us to come up with a humanistic and approachable, yet modern look and feel for the Modern ART [antiretroviral therapy] in South Africa project — something alive and opposite to the dry and sometimes depressing designs we see



Hearing is believing: the talking books sharing HIV information in South Africa - a photo essay



18:22

Coronavirus

THREE NEW FRIENDS

MR EAR MS N

DON'T FRIEND

(FORSOUT

'An economic calamity'
Africa faces years of post-Covid instability

I knew supply was coming / How Canada's push for Covid vaccines paid off

France / Police investigate rising number of fake Covid vaccine certificates

Explainer / Common Covid myths debunked

Live

ART IS CHANGING!

JUST KEE HEALTHY WILL PRO YGUR I FROM

Colourful Talk

@WhizzyMediaSA

whizzy Media

97 views · 2 months ago · 100% HELLO

Colourful Talk Podcast on Modern Art for South Africa! Dolutegravir! HIV/AIDS! Base! #Art / Activations! Soweto

Südafrika

Neue Variante mit vielen Mutationen

☰ Neue Zürcher Zeitung ☰

Omikron und HIV: Wenn Menschen zu Brutstätten für neue Coronavirus-Varianten werden

Eine ungenügende HIV-Behandlung ist nicht nur für die betroffene Person problematisch. Sie beschleunigt auch die Evolution von Sars-CoV-2 – mit unbekanntem Folgen für die Pandemie.

Alan Niederer
02.12.2021, 12:00 Uhr



Informative Graffiti zur Corona-Pandemie in einem Vorort von Johannesburg in Südafrika.

Kim Ludbrook / EPA

Ende letzter Woche ist bekanntgeworden, dass in Südafrika eine neue Variante des Pandemievirus aufgetaucht ist. Rasch kursierte der Verdacht, dass dies mit der dort grassierenden HIV-Epidemie in Verbindung stehen könnte. Den genauen Ursprung der

Modern ART made several appearances in the media.

As examples, the Guardian published a story about our talking book pilot project and one of our murals was used to illustrate a story in the New York Times about PrEP in South Africa.

TECHNICAL



The ADVANCE study to evaluate a candidate antiretroviral regimen

Willem D.F. Vermeulen
Consortium

Purpose of review

Current WHO-recommended first-line antiretroviral therapy is successful in saving millions of lives but

Recent findings

Two candidate antiretrovirals may substitute for the current first-line regimen, yielding a safer, more robust and cost-beneficial regimen over tenofovir disoproxil fumarate (TDF) and efavirenz (EFV). The regimen has been used in low- and middle-income countries, for commercial reasons.

Summary

We describe a large randomized controlled trial designed to evaluate the current first-line recommendation against a candidate first-line regimen. We will discuss the study design and discuss how we will disseminate the results.

Keywords

antiretrovirals, dolutegravir, first-line, tenofovir

INTRODUCTION

Since 2010, the WHO has recommended a single regimen as preferred first-line antiretroviral treatment (ART) for HIV that is well tolerated, has high efficacy and can be taken with first-line tuberculosis (TB) treatment (ref). Millions are now receiving the fixed-dose combination (FDC) of tenofovir disoproxil fumarate (TDF), lamivudine or interchangeable emtricitabine (FTC), often collectively referred to as TDF and efavirenz (EFV). The regimen has been very successful in treating tens of millions but has a low resistance barrier in the presence of even slightly new antiretrovirals at potentially similar or even lower prices than those in the current first-line regimen has led to consideration of the use of these agents in first-line treatment [1*,2,3**]. Tenofovir alafenamide (TAF; Gilead Health Sciences, California, USA) and particularly dolutegravir (DTG; ViiV Healthcare, London) are considered two potentially transformative antiretrovirals that address tolerability and toxicity as well as resistance for low-income

1746-630X Copyright © 2017 The Author(s). Published by Wolters Kluwer

Copyright © 2017 Wolters Kluwer

Current Opinion in HIV and AIDS

TOWARDS A UNIVERSAL ANTIRETROVIRAL REGIMEN: THE ADVANCE STUDY

The ADVANCE study: a groundbreaking trial to evaluate a candidate antiretroviral regimen

Vermeulen W.D.F., Clayton P.H., et al.

Current Opinion in HIV and AIDS, July 2017, Volume 12, Number 4, pp 300-305

DOI: 10.1097/COH.0000000000000289

Abstract

Purpose of review

Current WHO-recommended first-line antiretroviral therapy in low-income and middle-income countries has been very successful but still has toxicity concerns and a low

Recent findings

Two candidate antiretrovirals may substitute for the current first-line regimen, yielding a safer, more robust and cheaper regimen. Tenofovir disoproxil fumarate (TDF) and efavirenz (EFV) are replaced by dolutegravir (DTG) and lamivudine or emtricitabine (FTC), with substantial toxicity and cost benefits over tenofovir disoproxil fumarate (TDF) and efavirenz (EFV). However, these drugs are currently not available in low- and middle-income countries, for commercial reasons.

Summary

Study: a groundbreaking trial to evaluate universal antiretroviral

Polly Clayden¹, Celicia Serenata², for the OPTIMIZE

therapy in low-income and middle-income countries has been very successful in saving millions of lives but a major barrier to resistance.

Substantially transform first-line therapy in low-income and middle-income countries, yielding a safer, more effective and cheaper regimen. Tenofovir alafenamide carries toxicity and resistance. Dolutegravir could replace efavirenz, with substantial benefits. However, these drugs are currently not manufactured together in the same pill.

Randomised study testing a combination of these candidate antiretrovirals in low-income and middle-income countries that commenced recruitment in early 2017. We justify the trial with complex issues such as tuberculosis and pregnancy.

¹Wits Reproductive Health and HIV Institute, WHO

and middle-income countries (LMICs). Recent WHO guidelines have recommended DTG as an alternative to EFV [47,57]. Both agents are covered in detail in other articles in this issue of *Current Opinion*.

HISTORY OF THE ADVANCE STUDY

ADVANCE was conceived after a WHO Think Tank on ART Optimization at the 2015 Conference on

¹Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa and ²HIV i-Base, London, UK
Correspondence to Willem D.F. Venter, Wits Reproductive Health and HIV Institute, University of the Witwatersrand, 22 Estelin St & Klein St, Hillbrow, Johannesburg 2001, South Africa. Tel: +27 11 368 5300; e-mail: wventer@wits.ac.za

Curr Opin HIV AIDS 2017; 12:361–364
DOI:10.1097/COH.0000000000000389

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 International, which permits unrestricted use, distribution, and reproduction in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

© 2017 Wolters Kluwer Health | Lippincott Williams & Wilkins
www.co-hivandaids.com
All rights reserved.

For Authors > Journal Info > Editorial Board > Contact Us > Terms & Conditions > Privacy Policy > Copyright > Permissions > Advertising > Reprints & Permissions > Subscriptions > Backlist > Archives > Current Awareness > Alerts > Newsletters > Social Media > Help > Feedback > Contact Us

Edited by Charles M. Plummer, William B. Baruch, and Charles M. Plummer, for the OPTIMIZE Consortium.

Evaluate a candidate universal antiretroviral regimen for the OPTIMIZE Consortium.

Volume 12, Issue 6, June 2017

Submit Manuscript

ine therapy in low-income and middle-income countries, yielding a safer, more effective and cheaper regimen. Tenofovir alafenamide carries toxicity and resistance. Dolutegravir could replace efavirenz, with substantial benefits. However, these drugs are currently not manufactured together in the same pill.

Substantially transform first-line therapy in low-income and middle-income countries, yielding a safer, more effective and cheaper regimen. Tenofovir alafenamide carries toxicity and resistance. Dolutegravir could replace efavirenz, with substantial benefits. However, these drugs are currently not manufactured together in the same pill.

reasons.

Fit for purpose

Antiretroviral treatment optimisation

By Polly Clayden

HIV i-Base
May 2023

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

AUGUST 29, 2019

VOL. 381 NO. 9

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

W.D.F. Venter, M. Moorhouse, S. Sokhela, L. Fairlie, N. Mashabane, M. Masenya, C. Serenata, G. Alkporimie, A. Qavi, N. Chandivana, S. Norris, M. Chersich, P. Clayden, E. Abrams, N. Arulappan, A. Vos, K. McCann, B. Simmons, and A. Hill

ABSTRACT

BACKGROUND
Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries.

METHODS
We conducted a 96-week, phase 3, investigator-led, open-label, randomized trial in South Africa, in which we compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs — TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) — against the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group) or dard-of-care regimen of TDF-FTC-efavirenz (standard-care group). Inclusion criteria included an age of 12 years or older, no receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (50 ml per minute in patients younger than 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more per milliliter. The primary end point was the percentage of patients with week 48 HIV-1 RNA level of less than 50 copies per milliliter (as determined with a Snapshot algorithm from the Food and Drug Administration; noninferiority margin, -10 percentage points). We report the primary (48-week) efficacy and safety data.

RESULTS
A total of 1053 patients underwent randomization from February 2017 through May 2018. More than 99% of the patients were black, and 59% were female. The mean age was 32 years, and the mean CD4 count was 337 cells per cubic millimeter. At week 48, the percentage of patients with an HIV-1 RNA level of less than 50 copies per milliliter was 84% in the TAF-based group, 85% in the TDF-based group, and 79% in the standard-care group, findings that indicate that the DTG-containing regimens were noninferior to the standard-care regimen. The number of patients who discontinued the trial regimen was higher in the standard-care group than in the other two groups. In the per-protocol population, the standard-care regimen had equivalent potency to the other two regimens. The TAF-based regimen had less effect on bone density and renal function than the other regimens. Weight increase (both lean and fat mass) was greatest in the TAF-based group and among female patients (mean increase, 6.4 kg in the TAF-based group and among female group, and 1.7 kg in the standard-care group). No resistance to integrase inhibitors was identified in patients receiving the DTG-containing regimens.

CONCLUSIONS
Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen. There was significantly more weight gain with the DTG-containing regimens, especially in combination with TAF, than with the standard-care regimen. (ADVANCE ClinicalTrials.gov number, NCT03122262.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Venter at Estlisha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, 32 Princess of Wales Terr., Sunnyside Office Park, Block D, Floor 5, Johannesburg 2193, South Africa, or at wventer@wits.ac.za.
This article was published on July 24, 2019, at NEJM.org.

N Engl J Med 2019;381:803-15.
DOI:10.1056/NEJMoa1820224
Copyright © 2019 Massachusetts Medical Society.

All our community materials are informed by the latest scientific developments.

We were also part of the group that set up the ADVANCE trial and have reported on this and all the key ART optimisation studies and initiatives.



MODERN ART BY NUMBERS

2,633,950
LEAFLETS
DISTRIBUTED ACROSS
8 PROVINCES



3745 TEXTS

**ON THE TEAM'S
WHATSAPP GROUP**



@modernart4sa

3,500 FACEBOOK
FOLLOWERS

BABIES BORN
1



2,600
T-SHIRTS



2,800
WRISTBANDS

2,154
UNIQUE APP USERS/
WEBSITE VISITORS

modernartforsouthafrica.co.za



38,750
BOOKLETS
ON COVID-19

4
SOUTH AFRICAN
LANGUAGES

DISTRIBUTED
ACROSS 8
PROVINCES

- 55** WHATSAPP VIDEOS
- 5** ANIMATIONS
- 2** EXPLAINER VIDEOS
- 17** TRAINING VIDEOS

VIDEO

116,000
STICKERS

100,600
POSTERS
DISPLAYED IN
400 CLINICS
& HEALTHCARE FACILITIES
IN **84 COMMUNITIES**



2,100
TALKING BOOKS



13
TRAINING
SESSIONS

33
ACTIVATIONS
(2021-2023)

7,392 KM
DRIVEN

2,650
CANS OF
SPRAY PAINT

200
ENERGY
DRINKS

660
DRUM
STICKS
EATEN

20000 GB
DATA USED TO
DOWNLOAD
THE APP

50 DANCE
ROUTINES

300 CHILDREN
ATTENDED

5

LIMPOPO

36


GAUTENG

8

KWAZULU-NATAL

4

WESTERN CAPE




53 MURALS

6
CAPE
TOWN

5
LIMPOPO

8
DURBAN

34
JOBURG



530L
BLUE

530L
GREEN

1,060L
PINK

530L
YELLOW

530L
RED

3,710L
WHITE



CREDITS

CORE TEAM

Luckyboy Mkondwane
Polly Clayden
Suzanne Thompson
Nomatter Ndebele
Karien van der Westhuizen

ACTIVATION TEAM

Seeiso Wayne Letsie
Mbali Qwema
Tshewu Mosedi
Caroline Msimango
Thembisile Msimango
Thulina Moukangwe

GRAFFITI TEAM

SenzART 911
Lethuxolo Vusi Khumalo

SPECIAL THANKS

Francois Venter
Tracy Swan
Kenly Sikwese
Andrew Hill

TRAINERS

Lester Baloyi
Daniel Mathebula
Maria Mdakana
Professor Mtembu
Khulekani Gwala
Mary Nyathi
Puleng Tala
Andile Madondile
Sandile Khumalo
Godfrey Baloyi

DESIGN, APP & WEB

the earth is round
Karien van der Westhuizen
Elizna Rocher
Teneille Francis
Cindy de Bruyn

PHOTOGRAPHY

Thom Pierce
Team members

*Dedicated to Celia
Serenata and Andrew
Mosane. Two fearless
ART optimisers.
We miss them.*



MODERNARTforSOUTHAFRICA.CO.ZA